Nuo Therapeutics, Inc. (AURX) Stock

About Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.

Nuo Therapeutics, Inc. is headquartered in US.

Nuo Therapeutics, Inc. (AURX) stock trades at $1.00 with a market capitalization of $48.41M. The stock is valued at a price-to-earnings (P/E) ratio of -20.00, price-to-book of -34.89, price-to-sales of 11.72. Over the past 52 weeks the stock has ranged between $0.84 and $3.23, and currently trades 69.0% below its 52-week high.

On profitability, Nuo Therapeutics, Inc. generates a return on equity (ROE) of 266.09% — well above the market average, a sign of a high-quality business, return on capital employed of -384.78%, an operating margin of -53.69%, a net profit margin of -57.72%.

Official website: www.nuot.com